Fred Grossman D.O., Fapa Email & Phone Number

Philadelphia, Pa, Us

Clinical stage biotech developing proprietary multi-modal treatments focusing on Tregs, targeting significant unmet medical needs across neurodegenerative and autoimmune disorders.

Reunion Neuroscience was Acquired and is a Private Company

Genetic engineering CNS company dedicated to developing neuroactive compounds from mycogenic and phytogenic fungi and plants including psilocybin, cannabis, DMT to treat the most severe neuropsychiatric and neurologic disorders

Melbourne, Vic, Au

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medications. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three candidates in phase 3 trials including acute graft vs host disease, chronic heart failure, and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from bone marrow of healthy adults and creates master cell banks which are industrially expanded without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore, and Texas and is listed on the Australian Securities Exchange (MSB) and Nasdaq (MESO).

Wilmington, Delaware, Us

NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company developing a pipeline of novel therapeutics for the treatment of central nervous system disorders. The novel pipeline is based on a deep understanding of the role of the N-methyl-D-aspartate (NMDA) receptor. The lead program is NRX-100/NRX-101, the first potential sequential drug regimen for Bipolar Depression in patients with Acute Suicidal Ideation & Behavior. The pipeline also includes programs for PTSD with Acute Suicidal Ideation and Behavior.

Mumbai, Maharashtra, In

Mumbai, Maharashtra, In

Lead innovative Global Clinical Development, Pharmacovigilance, and Medical Affairs and corporate strategy across the R & D pipeline and portfolio of products from Phase I through phase III and approvals including biologics (monoclonal antibodies including bispecific technology) and small molecules across oncology, immunology, respiratory, and dermatology therapeutic areas. Lead the company's 1st NDA, Ryaltris. Also responsible for the generics, ANDA, 505(b)(2), and biosimilar portfolio.

Marlborough, Ma, Us

Lead Global Clinical Development & Medical Affairs across all therapeutic areas including CNS, Respiratory, Biotherapeutics, Stem Cells, and Oncology.

Marlborough, Ma, Us

Lead Medical Affairs Functions and Drug Safety and Pharmacovigilance across all therapeutic areas

Lawrence Township, Nj, Us

Vice President, Neuroscience Medical Strategy, US Medical 2009-Present- Leads diverse team of Medical professionals including Strategic Medical Team, MSL's, Medical Information, Publication and Communication, Medical Education, across the matrix and US Business in Neuroscience and co-lead strategic alliance partnerships- Leads Global lifecycle management of Abilify including phase IIIb and IV clinical studies and Health Authority negotiations, Post-marketing and Outcomes trials, IST’s, medical education, publication and education plans and thought leader interactions. Optimize label using studies and negotiating with FDA and Global Health Authosities. - Develop U.S. strategy across neuroscience portfolio of different assets including Alzheimer’s disease, depression, and schizophrenia- Support market access and negotiate with managed care and health care agencies and across US- Develop disease focused plans in neuroscience to support overall strategic needs and help develop portfolio- Advisor, Neuroscience, BMS Foundation, Charitable Contributions

Lawrence Township, Nj, Us

Leading diverse team in Global Medical Affairs and Health Outcomes/Database Research across entire portfolio of products including oncology, immunology, virology, neuroscience, cardiovascular, and metabolics. Develop disease platforms and strategy based on unmet medical need, design and execute studies to support strategy and label optimization, communication, and publications and medical education. Provide deep payer insights into development plans, compile economic dossiers to support reimbursement.

Lawrence Township, Nj, Us

Responsible for all medical and regional research activities across region. Data generation and dissemination, medical strategy, market access, and medical support for launch products and health technology assessments. Also lead Global lifecycle and aliances for key psychiatric asset.

Lawrence Township, Nj, Us

Lead phase IIIb-IV and sNDA/NDA submissions (Neuroscience), create and execute global medical strategy and studies, negotiate with regulatory authorities, develop medical education and publication strategy, lead diverse team across therapeutic areas.

New Brunswick, Nj, Us

Lead Global strategy for psychiatry research and development for phase I - IIIb. Managed 4 global multidisciplanary development teams, Chair L & A group, direct negotiations with FDA and health authorities.

New Brunswick, Nj, Us

Phase II-IIIb for atipsychotic and neuroscience development programs; create clinical development plans and strategy.

Indianapolis, Indiana, Us

Antidepressant team responsible for development program of antidepressant portfolio.

As a Partner in one of the largest and most successful physician psychiatric practices in the Delaware Valley, Psychiatric Consultants LLC was associated with numerous psychiatric and medical hospitals including academic institutions in Philadelphia. The year on year growth was substantial, providing care and consultation across the Philadelphia area.